{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"45.4","value":"15"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"43.4","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"CBR is defined as the percentage of participants achieving a complete remission (CR), complete marrow remission (mCR), partial remission (PR), stable disease (SD) lasting at least 8 weeks, or hematologic improvement (HI), per International Working Group (IWG) criteria, where CR=Bone marrow:\\<=5 percent(%) myeloblasts with normal maturation of all cell lines; PR=Bone marrow blasts decreased by \\>=50% over pre-treatment but still \\>5%; mCR=Bone marrow: \\<=5% myeloblasts and decrease by \\>=50% over pre-treatment; SD= Failure to achieve at least PR, but no evidence of progression \\>8 weeks; HI=Erythroid (E): hemoglobin increase of \\>1.5 grams per deciliter (g/dL), HI-Platelet: increase of \\>30,000/milliliter (mL) (starting with \\>20,000/mL) and increase from \\<20,000/mL to \\>20,000/mL by \\>100%; HI-Neutrophil: increase of \\>100% and \\>500/microliter. Percentage values are rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG000","title":"Part 1: GSK3326595 400 mg"},{"description":"Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG001","title":"Part 1: GSK3326595 300 mg"}],"paramType":"NUMBER","populationDescription":"All Treated Population consisted of all participants who received at least one dose of GSK3326595 as monotherapy or at least one dose of both combination drugs as combination treatment.","reportingStatus":"POSTED","timeFrame":"Up to 30.8 months","title":"Part 1: Percentage of Participants With Clinical Benefit Rate (CBR)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}